Streetbeat News

Analyst Ratings

ALPN

Alpine Immune Sciences (NASDAQ:ALPN) received mixed analyst ratings with 1 bullish and 5 somewhat bullish over the past three months. The average 12-month price target increased to $28.5, up 45.41% from the previous $19.60, with a high estimate of $35.00 and a low of $22.00. Analysts from firms like Wedbush and Morgan Stanley have raised their price targets, reflecting positive sentiment towards ALPN's market position and financial health, despite its revenue growth trailing the Health Care sector average.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 2:00 pm

LUV

Southwest Airlines (NYSE:LUV) has received mixed evaluations from 7 analysts in the last three months, with an average 12-month price target of $32.71, down from $33.17. Analysts' ratings range from 'Outperform' to 'Underperform', with recent actions including both raised and lowered price targets. Southwest is the largest domestic air carrier in the U.S., operating a low-cost business model. Financially, it has shown a revenue growth of 4.9%, a net margin of 2.96%, an ROE of 1.77%, an ROA of 0.53%, and a healthy debt-to-equity ratio of 0.84.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 2:00 pm

FUSN

Fusion Pharmaceuticals (NASDAQ:FUSN) has received mixed evaluations from 6 analysts in the past three months, with recent sentiment slightly less bullish than the previous month. The average 12-month price target for FUSN is now $14.00, up from $13.25, with a high estimate of $16.00 and a low of $12.00. Analysts from Wedbush, Raymond James, Oppenheimer, and RBC Capital have provided ratings and adjusted price targets, reflecting their views on the company's performance and market conditions. Fusion Pharmaceuticals is a clinical-stage biopharmaceutical company developing treatments for cancer. Despite a significant revenue growth rate of 1108.43% as of September 30, 2023, the company's financial health indicators such as net margin and ROE are below industry standards, although it has a low debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

January 26, 2024 | 2:00 pm

CNOB

Keefe, Bruyette & Woods analyst Michael Perito has maintained an Outperform rating on ConnectOne Bancorp (NASDAQ:CNOB) and increased the price target from $25 to $27.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:59 pm

CFR

Keefe, Bruyette & Woods analyst Brady Gailey has maintained a 'Market Perform' rating on Cullen/Frost Bankers (NYSE:CFR) but reduced the price target from $125 to $118.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:57 pm

BX

Wells Fargo analyst Timothy O'Shea has maintained an Overweight rating on Blackstone (NYSE:BX) and increased the price target from $130 to $134.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:57 pm

BX

Keefe, Bruyette & Woods analyst Michael Brown has maintained a 'Market Perform' rating on Blackstone (NYSE:BX) and increased the price target from $123 to $127 as reported on January 25, 2024.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:56 pm

XEL

Wells Fargo analyst Neil Kalton has maintained an Equal-Weight rating on Xcel Energy (NASDAQ:XEL) and increased the price target from $63 to $64.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:54 pm

BRO

Keefe, Bruyette & Woods analyst Meyer Shields has maintained an Underperform rating on Brown & Brown (NYSE:BRO) but increased the price target from $70 to $75.

Portfolio Pulse from Benzinga Newsdesk

January 26, 2024 | 1:54 pm

SCCO

TSLA

UBER

Tesla, Inc. (TSLA) shares fell over 12% after reporting Q4 revenue and EPS that missed consensus estimates. Southern Copper Corporation (SCCO) was downgraded by Morgan Stanley from Equal-Weight to Underweight with a reduced price target. Uber Technologies, Inc. (UBER) reached a new all-time high and is showing interest in federal marijuana lobbying, which could benefit from the SAFE Banking Act.

Portfolio Pulse from Avi Kapoor

January 26, 2024 | 1:53 pm